Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype

Seho Park, Byeong Woo Park, Tae Hyun Kim, Chang Wan Jeon, Han Sung Kang, Jung Eun Choi, Ki Tae Hwang, In Cheol Kim

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: This study was designed to evaluate the impact of lack of either estrogen receptor (ER) or progesterone receptor (PR) on characteristics and outcomes among luminal A breast cancer subtype treated with endocrine with or without chemotherapeutic agents. Methods: The luminal A subtype was categorized into three subgroups: ER+/PR+, ER+/PR-, and ER-/PR+. All tumors were human epidermal growth factor receptor 2 (HER2) negative. Clinicopathological features and survival were analyzed using the Severance Hospital dataset (n = 1,180) and were validated by the nationwide Korean Breast Cancer Society (KBCS) registry (n = 9,916). Results: Despite the different distribution of ER/PR status, tumor stage, grade, and local therapies between the two datasets, similarly ER+/PR+ showed smaller size and good differentiation, ER+/PR- patients had the oldest age at diagnosis, and ER-/PR+ was associated with the youngest age at onset and grade III tumor. Single hormone receptor-positive subgroups demonstrated worse disease-related outcomes than the ER+/PR+ subgroup. These associations were confirmed by the KBCS dataset. This trend was also demonstrated in the subpopulation of 1,944 patients with Ki-67 < 14 %. Inferior survival of single receptor-positive tumors was more definite among node-positive patients even when receiving both chemo-endocrine therapies. Conclusions: Current results suggest that the luminal A subtype is also heterogeneous and each subgroup has unique clinicopathologic characteristics. Lack of either ER or PR expression is associated with worse survival, especially among node-positive luminal A subtype.

Original languageEnglish
Pages (from-to)1505-1513
Number of pages9
JournalAnnals of Surgical Oncology
Volume20
Issue number5
DOIs
Publication statusPublished - 2013 May 1

Fingerprint

Progesterone Receptors
Estrogen Receptors
Breast Neoplasms
Survival
Neoplasms
Age of Onset
Registries
Hormones

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Park, Seho ; Park, Byeong Woo ; Kim, Tae Hyun ; Jeon, Chang Wan ; Kang, Han Sung ; Choi, Jung Eun ; Hwang, Ki Tae ; Kim, In Cheol. / Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype. In: Annals of Surgical Oncology. 2013 ; Vol. 20, No. 5. pp. 1505-1513.
@article{87820f71f50e48cfb2470499e802c4d6,
title = "Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype",
abstract = "Background: This study was designed to evaluate the impact of lack of either estrogen receptor (ER) or progesterone receptor (PR) on characteristics and outcomes among luminal A breast cancer subtype treated with endocrine with or without chemotherapeutic agents. Methods: The luminal A subtype was categorized into three subgroups: ER+/PR+, ER+/PR-, and ER-/PR+. All tumors were human epidermal growth factor receptor 2 (HER2) negative. Clinicopathological features and survival were analyzed using the Severance Hospital dataset (n = 1,180) and were validated by the nationwide Korean Breast Cancer Society (KBCS) registry (n = 9,916). Results: Despite the different distribution of ER/PR status, tumor stage, grade, and local therapies between the two datasets, similarly ER+/PR+ showed smaller size and good differentiation, ER+/PR- patients had the oldest age at diagnosis, and ER-/PR+ was associated with the youngest age at onset and grade III tumor. Single hormone receptor-positive subgroups demonstrated worse disease-related outcomes than the ER+/PR+ subgroup. These associations were confirmed by the KBCS dataset. This trend was also demonstrated in the subpopulation of 1,944 patients with Ki-67 < 14 {\%}. Inferior survival of single receptor-positive tumors was more definite among node-positive patients even when receiving both chemo-endocrine therapies. Conclusions: Current results suggest that the luminal A subtype is also heterogeneous and each subgroup has unique clinicopathologic characteristics. Lack of either ER or PR expression is associated with worse survival, especially among node-positive luminal A subtype.",
author = "Seho Park and Park, {Byeong Woo} and Kim, {Tae Hyun} and Jeon, {Chang Wan} and Kang, {Han Sung} and Choi, {Jung Eun} and Hwang, {Ki Tae} and Kim, {In Cheol}",
year = "2013",
month = "5",
day = "1",
doi = "10.1245/s10434-012-2772-x",
language = "English",
volume = "20",
pages = "1505--1513",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "5",

}

Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype. / Park, Seho; Park, Byeong Woo; Kim, Tae Hyun; Jeon, Chang Wan; Kang, Han Sung; Choi, Jung Eun; Hwang, Ki Tae; Kim, In Cheol.

In: Annals of Surgical Oncology, Vol. 20, No. 5, 01.05.2013, p. 1505-1513.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype

AU - Park, Seho

AU - Park, Byeong Woo

AU - Kim, Tae Hyun

AU - Jeon, Chang Wan

AU - Kang, Han Sung

AU - Choi, Jung Eun

AU - Hwang, Ki Tae

AU - Kim, In Cheol

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Background: This study was designed to evaluate the impact of lack of either estrogen receptor (ER) or progesterone receptor (PR) on characteristics and outcomes among luminal A breast cancer subtype treated with endocrine with or without chemotherapeutic agents. Methods: The luminal A subtype was categorized into three subgroups: ER+/PR+, ER+/PR-, and ER-/PR+. All tumors were human epidermal growth factor receptor 2 (HER2) negative. Clinicopathological features and survival were analyzed using the Severance Hospital dataset (n = 1,180) and were validated by the nationwide Korean Breast Cancer Society (KBCS) registry (n = 9,916). Results: Despite the different distribution of ER/PR status, tumor stage, grade, and local therapies between the two datasets, similarly ER+/PR+ showed smaller size and good differentiation, ER+/PR- patients had the oldest age at diagnosis, and ER-/PR+ was associated with the youngest age at onset and grade III tumor. Single hormone receptor-positive subgroups demonstrated worse disease-related outcomes than the ER+/PR+ subgroup. These associations were confirmed by the KBCS dataset. This trend was also demonstrated in the subpopulation of 1,944 patients with Ki-67 < 14 %. Inferior survival of single receptor-positive tumors was more definite among node-positive patients even when receiving both chemo-endocrine therapies. Conclusions: Current results suggest that the luminal A subtype is also heterogeneous and each subgroup has unique clinicopathologic characteristics. Lack of either ER or PR expression is associated with worse survival, especially among node-positive luminal A subtype.

AB - Background: This study was designed to evaluate the impact of lack of either estrogen receptor (ER) or progesterone receptor (PR) on characteristics and outcomes among luminal A breast cancer subtype treated with endocrine with or without chemotherapeutic agents. Methods: The luminal A subtype was categorized into three subgroups: ER+/PR+, ER+/PR-, and ER-/PR+. All tumors were human epidermal growth factor receptor 2 (HER2) negative. Clinicopathological features and survival were analyzed using the Severance Hospital dataset (n = 1,180) and were validated by the nationwide Korean Breast Cancer Society (KBCS) registry (n = 9,916). Results: Despite the different distribution of ER/PR status, tumor stage, grade, and local therapies between the two datasets, similarly ER+/PR+ showed smaller size and good differentiation, ER+/PR- patients had the oldest age at diagnosis, and ER-/PR+ was associated with the youngest age at onset and grade III tumor. Single hormone receptor-positive subgroups demonstrated worse disease-related outcomes than the ER+/PR+ subgroup. These associations were confirmed by the KBCS dataset. This trend was also demonstrated in the subpopulation of 1,944 patients with Ki-67 < 14 %. Inferior survival of single receptor-positive tumors was more definite among node-positive patients even when receiving both chemo-endocrine therapies. Conclusions: Current results suggest that the luminal A subtype is also heterogeneous and each subgroup has unique clinicopathologic characteristics. Lack of either ER or PR expression is associated with worse survival, especially among node-positive luminal A subtype.

UR - http://www.scopus.com/inward/record.url?scp=84880071799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880071799&partnerID=8YFLogxK

U2 - 10.1245/s10434-012-2772-x

DO - 10.1245/s10434-012-2772-x

M3 - Article

C2 - 23192228

AN - SCOPUS:84880071799

VL - 20

SP - 1505

EP - 1513

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 5

ER -